Cross-border team advises on US$5.8bn health tech merger

Norton Rose Fulbright's US, Paris and Brussels offices represented Medidata, a market-leading clinical cloud solutions company, during its merger with French software company Dassault Systèmes in a deal worth US$5.8 billion on an enterprise value basis.

The transaction was unanimously approved by the Boards of Directors of Medidata (NASDAQ: MDSO) and Dassault Systèmes (PAR:DSY) and is expected to close in the fourth quarter of 2019 pending regulatory approvals.

Medidata's software is used to help pharmaceutical, medical device and other companies conducting clinical trials by providing the life sciences industry with an integrated business experience platform for an end-to-end approach for research and discovery, development, clinical testing, manufacturing and commercialization of new therapies and health technologies.

The team was led by Warren Nimetz and Paul Jacobs (New York) and included Sheldon Nussbaum (New York), Donald Ainscow (Dallas), Jennifer Huh, Leslie Hung (New York), Dan Wellington, Larry G. Franceski (Washington, DC), David Gallai (New York), Christian Filippitsch (Brussels) and Antoine Colonna d'Istria (Paris).